Targeted therapy for hepatocellular carcinoma: Challenges and opportunities
from Cancer Letters
From July 25:
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, which ranks as the sixth of cancer-related death. Despite the emergence of targeted therapy, advanced-stage HCC remains largely incurable due to low response rate and therapeutic resistance. In this review, we mainly focused on the current progression of multi-kinase inhibitors and immunotherapies in the treatment of HCC.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063